Study to Determine the Safety and Efficacy of Teneligliptin (20 Mg) in Naive Type 2 Diabetes Mellitus
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2023, Vol 3, Issue 3
Abstract
Background: Teneligliptin is a novel, highly selective DPP-4 inhibitor with long half-life, approved in Japan (2012) and in Korea (2014) to treat patients of type 2 DM. It is characterized by a considerably rigid structure formed by five consecutive rings.Teneligliptin, 20mg/day as monotherapy and combination therapy in type 2 DM was shown to be effective in reducing HbA1c and fasting plasma glucose levels without any significant adverse events. Present study was conducted to determine the safety and efficacy of Teneligliptin (20 mg) in naive type 2 diabetes mellitus. Materials and methods:The present study was a hospital based prospective study undertaken to study the safety and efficacy of teneligliptin (20 mg) in naïve type 2 diabetes mellitus. Newly diagnosed type 2 diabetes mellitus patients within age group 18-70 years were studied. All patients were assessed for Blood sugar levels (Fasting and Postprandial HbA1C, Serum urea, Serum Creatinine, Serum uric acid, Lipid profile and ECG. Results: The mean age of total patients was 52.86 ±9.24 years. The mean HbA1c among patients with DM was 7.76 ±1.61. The mean serum urea was 29.12±6.58mg/dl while Serum creatinine was 1.08±0.18 mg/dl. The mean fasting Blood sugar of the patients before treatment was 123.55 ±10.72 and 103.12 ±8.63 mg/dl after treatment with statistical significant difference (p<0.05). The mean blood urea of the patients before treatment was 29.12 ±6.58 and 20.86 ±5.04 mg/dl after treatment with no statistical significant difference. (p >0.05) The mean QT interval of the patients before treatment was 0.37±0.03 and 0.38±0.03 seconds after treatment with statistical non-significant difference (p <0.05). Conclusion: The present study concludes that, Teneligliptin, a novel DPP-4I, when prescribed as a monotherapy antidiabetic agent in a dose of 20 mg daily, significantly improved glycemic parameters. The results of this study suggest that teneligliptin can be considered to be an effective antidiabetic agent in the management of Indian patients with type naive 2 Diabetes Mellitus.
Authors and Affiliations
Subhash Chandra , Pulkit Chaudhary , Vagish Baranwal
Keywords
Related Articles
- EP ID EP739963
- DOI 10.47191/ijmscrs/v3-i3-40
- Views 57
- Downloads 0
Accessibility of End-Stage Renal Disease Patients to Health Care Services of a Specialized Hospital
Objective:This study was conducted to assess accessibility of ESRD patients to health care services of a specialized hospital.Methods:The study was a cross-sectional study, which was conducted at the National...
Medical Causes of Death’s Profile Based on ICD-10 Standards in Confirmed Covid-19 Patients in Tertiary Hospital in Padang, Indonesia
Medical causes of death written by a doctor are important to be documented for each death, especially in relation to public health, research, surveys, epidemiology, prevention programs, public safety, medicine, and healt...
Clinical Considerations in Specialized Nutrition in Critically III Patients
Specialized nutrition support (SNS) is required when oral intake is either limited or not possible for a prolonged period of time. Common indications for SNS include patients in critical care, those with dys...
ncidenceofIntestinalObstructionSecondarytoPetersen'sHerniaafterLaparoscopicRoux-en-YGastricBypass
Objective:IdentifytheincidenceofPetersen'sherniaingastricbypasspatientsatourinstitution.Summary:Laparoscopicgastricbypasshasprovedtobethebesttreatmentforobesityandtheresolutionoftheircomplications,however,itpresentslong-...
Pseudoexfoliation syndrome in a patient with subluxation of the lens secondary to homocystinuria
This article aims to comprehensively describe a particular case of bilateral intraocular subluxated lens with pseudoexfoliation syndrome in a Moroccan woman with homocystinuria. We report a case of a 56-year-old patient...